MedinCell S.A. (MDCLF) Discusses U.S. Approval of Weltruza and Its Impact on Schizophrenia Treatment and Financial Outlook Transcript

MedinCell S.A. (MDCLF) discussed the U.S. approval of Weltruza and its impact on schizophrenia treatment and financial outlook in a recent transcript.

Want to stay up to date with the world events at sea or at home?

Explore Navvyx News - the best News app for seafarers.

Join Navvyx - it's Free